Larimar Projects Cash Into Late Second Quarter 2027 — Its Conditional Launch Target Comes Later
Manufacturing spending fell as Larimar increased commercial preparations for nomlabofusp, its experimental Friedreich’s ataxia treatment.
Larimar Therapeutics, which is developing nomlabofusp for Friedreich’s ataxia, said Monday its $128.7 million in cash and securities should fund operations into late second quarter 2027. Its earnings release, accompanying an SEC filing, puts the potential U.S. launch target in the third quarter of 2027, if approved.
Manufacturing Costs Fall, Launch Spending Rises
Larimar's third-quarter loss narrowed to $31.1 million, or $0.29 per common share, from $47.7 million, or $0.61 per share, a year earlier. Research spending fell to $25.9 million from $44.9 million; Larimar attributed the decline mainly to a $19.3 million decrease in work at outside drug manufacturers.
Administrative costs rose to $6.5 million from $4.6 million. Management attributed the increase primarily to faster commercial preparations, including additional consulting, legal work, staff costs and stock awards.
For the first nine months of 2026, the loss was $93.5 million, or $0.90 per common share, versus $103.2 million, or $1.50 per share, a year earlier. Research spending declined to $79.0 million from $94.9 million, while administrative spending increased to $19.0 million from $13.6 million.
Larimar attributed the nine-month research decline mainly to $20.1 million less in manufacturing costs. A $4.1 million increase in professional, software and consulting fees partly offset that reduction, covering clinical trials, data analysis, FDA inspection preparations and application work.
Nomlabofusp Moves Toward FDA Review
Larimar completed its approval application last Monday, seeking accelerated approval for adults and children with Friedreich’s ataxia. The genetic disease results from insufficient frataxin, a protein nomlabofusp is designed to deliver to cells’ mitochondria through injections under the skin.
The company's 2025 annual-report profile places substantially all its resources in nomlabofusp development and supporting operations. Its program has completed four clinical studies, with approximately 8,000 doses administered across clinical development.
Larimar previously said the FDA was willing to consider skin frataxin levels as a potential substitute for measuring clinical benefit. Previously reported open-label findings showed sustained increases in that measure and directional improvements in clinical outcomes against a natural-history reference population.
Patients are enrolling in FORWARD-FA, the global late-stage confirmatory trial. Enrollment also continues in the open-label study; in November, Larimar presented previously reported findings and new lipid and gene-expression analyses at the 2026 International Congress for Ataxia Research.
A Conditional 2027 Launch
Carole Ben-Maimon, Larimar's chief executive officer, said, “we are preparing for a potential U.S. launch in the third quarter of 2027, if approved,” while the company evaluates options for commercialization globally.
Larimar expects FDA acceptance of the application in early 2027 and an open-label safety update in the first quarter of 2027. Its potential milestones include U.S. approval in mid-2027 and obtaining and selling a rare pediatric disease priority review voucher in mid-2027, if approved.
The company's projected funding extends into late second quarter 2027; its launch preparations target the following quarter, contingent on FDA approval.
Sources
- 8-K Filing — Larimar Therapeutics, Inc. (LRMR) — SEC EDGAR
- Exhibit lrmr-ex99_1.htm — Larimar Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Larimar Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- 8-K filed 2026-11-09 — Larimar Therapeutics, Inc. (earlier disclosure) — SEC EDGAR